INDEX

Note: Page numbers of article titles are in boldface type.

Aluminum, in feline vaccines, and fibrosarcoma, 104 and inflammation, 106–107
Amputation, for bone tumors, 135–143 problems associated with, 138–139 suitable candidates for, 136 techniques of, 136 for canine osteosarcoma, 113, 123–133 immunotherapy with, medial survival times following, 125, 127 Animal interests, in clinical trials, 34 L-Asparaginase, for canine lymphoma, 66–67 Basal cell carcinoma, of skin, radiation for, 23 Bayesian theory, and clinical tests, 53 Biologic response modifiers, for cancer treatment, 3, 7 Bone marrow, examination of, with mast cell tumors, 93 Bone tumors, amputation for, 135–143 problems associated with, 138–139 suitable candidates for, 136 techniques of, 136 limb-sparing surgery for, amputation vs, 135–143 Kaplan-Meier survival curve for, 140 problems associated with, 139 expense, 141 implant loosening/failure, 141 infection, 139–141 local tumor recurrence, 139 suitable candidates for, 137 techniques of, 136–137 malignant, Kaplan-Meier survival curves for, 138

Cancer. See also Carcinoma and other specific cancers.

biologic response modification for, 3 chemotherapy for, 2 hyperthermia for, 3 immunotherapy for, 3 literature on, keeping up to date with, 40–41 multimodality therapy in, 1–8 quality of life in, 5 radiation therapy for, 2 surgery for, 2, 9–16 ways to treat, 2–3 Canine hemangiosarcoma, 51–58. See also Hemangiosarcoma.
Canine lymphoma, 63–71, 73–85. See also Lymphoma.
Canine lymphoma monoclonal antibody 231, for canine lymphoma, 76–82 Canine osteosarcoma, 111–121. See also Osteosarcoma.
Carcinoma, radiation for, head/neck, 19–20 nasal, 20 oral squamous cell, 20–21 skin, 23 thyroid, 21 Case-control studies, descriptive information in, 45–47 evaluation of, 46 Case reports, 30–31 descriptive information in, 43 Case series, descriptive information in, 44–45 Cats, postvaccinal sarcoma in, role of inflammation in, 103–109 Central nervous system, epithelial tumors of, radiation for, 22 sarcoma of, radiation for, 26 Chemoimmunotherapy, for cancer, 7 for canine osteosarcoma, 123–133 Chemotherapy, for cancer, 2 adjunctive, aggressiveness of, 15 adjuvant, 4 timing of, 13
Chemotherapy (Continued)
effectiveness of, 11-12
neoadjuvant, 5-6
for mast cell tumors, 97
Cisplatin, for canine osteosarcoma
micrometastases, 116-118
doxorubicin with, 118-119
protocols for, 117
Clinical appraisal, clinical reality vs, 39-61
Clinical literature, data in, sources of, 47-49
cautions in, 48
clinical reality of, 48-49
descriptive information in, sources of, 43-47
diagnosis, 52-55
selection and interpretation of tests, 52-54
evaluation of, 39-61
therapeutic intervention, 55-58
evaluation of reports, 55-57
types of, 30-33
comparison of, 35-36
Clinical reality, clinical appraisal vs, 39-61
Clinical test, accuracy of, 53
usefulness of, 52
validity of, 52
Clinical trials, in veterinary oncology, 29-37
value to humanity, 35
value to veterinary medicine, 34-35
Coagulation abnormalities, with mast cell tumor, medical support in, 100
Corticosteroids, for canine lymphoma, 64
for mast cell tumors, 97
Cyclophosphamide, for canine lymphoma, 64, 66
Cyclosporine, for mast cell tumors, 98
Cytology, value of, 13

Descriptive information, in clinical literature, commonness of disease, 49-50
likelihood of contracting disease, 50-51
sources of, 43-47
Dexamethasone, for mast cell tumors, 98
Dogs, osteosarcoma in, 111-121. See also Osteosarcoma.
Doxorubicin, for canine lymphoma, 64-65
for canine osteosarcoma micrometastases, 118
cisplatin with, 118-119

Epidermis, carcinoma of, radiation for, 23
Epithelial neoplasia, radiation for, 19-24
Epulides, radiation therapy for, 157
Etoposide, for canine lymphoma, 64
Evidence-based medicine, 41-42

Feline leukemia virus, and fibrosarcoma, 104
Fibrosarcoma, feline leukemia virus and, oral, canine, 148
radiation therapy for, 160
vaccine-associated, treatment for, 7

Gastroduodenal ulceration, with mast cell tumor, medical support in, 99
Glucocorticoids, for mast cell tumors, 97

Head, carcinoma of, radiation for, 19-20
Hemangiosarcoma, canine, commonness of disease, 51
diagnostic tests for, 53
information on, 54-55
likelihood of contracting, 51
literature on, 42
therapy for, clinical trials of, 57-58
Hemolymphatic neoplasm, radiation for, 17-19
Hyperthermia, for cancer treatment, 3
for fibrosarcoma, 7-8
Hypotensive shock, with mast cell tumor, medical support in, 99

Immunomodulators, for canine osteosarcoma, 124
Immunotherapy, for cancer, 3
adjunctive, aggressiveness of, 15
Implant loosening/failure, with limb-sparing surgery for bone tumors, 141
Inflammation, as promoter of tumor development, 105

Laboratory data, 47-48
Limb-sparing surgery, for bone tumors, 135-143
Kaplan-Meier survival curve for, 140
problems associated with, 139
expense, 141
implant loosening/failure, 141
infection, 139-141
local tumor recurrence, 139
suitable candidates for, 137
techniques of, 136-137
Liposomal muramyl tripeptide-phosphatidylethanolamine (L-MTP-PE), postamputation, for canine osteosarcoma, 126-130
Lymphoma, canine, 63-71
biological dilemmas involving, 75
chemoimmunotherapy for, 73-85
canine lymphoma monoclonal antibody 231, 76-82
nonspecific and active, 75-76
chemotherapy for, combination, 65-66
future directions in, 67-69
single-agent, 64-65
summary of results, 74
radiation for, 17-18
aggressiveness of, 83
conclusions and controversies in, 82-84
future of, 84
multivariate analysis of, 82
patient preselection in, 83
phase 1 clinical trial of, 77
prognosis with, 80
protocols for, 78
remission with, 79
results with, 81
selection criteria for, 77
Mouth, squamous cell carcinoma of,
radiation for, 20-21
tumors of, 145-153
Multimodality therapy, in cancer, 1-8

Malignancy, owner reluctance to treat, 14
Malignant melanoma, oral,
mandibulectomy for, 147
radiation therapy for, 157-158
Mammary gland carcinoma, radiation for, 24
Mandibulectomy, in canine oral cancer, 146-148
complications in, 146
survival times in, 147
Mast cell(s), clinical facts about, 87-88
Mast cell tumors, 87-102
canine vs feline, 94-95
chemotherapeutic dilemmas in, 96-98
clinical facts about, 88-89
clinical signs of, 88
deionized water treatment of, 96
diagnostic evaluation of, challenges in, 91-94
definitive, 92
grading and staging of, 90-91
metastatic, documentation of, 92-93
metastatic pattern of, 89
paraneoplastic disorders with, clinical signs of, 94
medical support in, 98-100
preoperative diagnosis of, 95
proposed etiologic origin, 89-90
radiation for, 18
regional node enlargement with, 93
surgical management of, 95-96
surgical margins in, 96
Maxillectomy, in canine oral cancer, 148-150
survival times in, 149
Melanoma, radiation for, 25-26
Mesenchymal tumors, radiation for, 24-25
Methotrexate, for canine lymphoma, 66
Mitoxantrone, for canine lymphoma, 65
Monoclonal antibody 231, for canine lymphoma, 76-82
Nasal carcinoma, radiation for, 20
Neck, carcinoma of, radiation for, 19-20
Neoplasia, epithelial, radiation for, 19-24
hemolymphatic, radiation for, 17-19
oral, 145-153, 155-163. See also Oral cancer.
Nose, carcinoma of, radiation for, 20

Oncology, surgical, 9-16
veterinary, clinical trials in, 29-37
Oral cancer, 145-153, 155-163
canine, mandibulectomy in, 146-148
maxillectomy in, 148-150
chemotherapy in, 151-152
feline, 150-151
radiation therapy for, 155-163
specific tumors, 157-161
Oral tumors, 145-153
Osteosarcoma, canine, 111-121
diagnostic evaluation of, 112-113
incidence and biologic behavior of, 111-112
long-term patient monitoring in, 119
micrometastases, treatment of, 114-119
goal of, 115
response to, 116
oral, 148
primary, treatment of, 113-114
relapse in, 123
survival data on, 115
treatment of, 123-133
clinical studies of, 126-128
radiation for, 26
Perianal gland tumors, radiation for, 23-24
Pet owner, attitude in malignancy, 14
Prednisolone, for mast cell tumors, 97
Prednisone, for canine lymphoma, 64, 66 for mast cell tumors, 97
Prior probability, definition of, 53
Prospective clinical trials, 32–33

Quality of life, in cancer, 5

Rabies vaccine, feline, and fibrosarcoma, 104
Radiation therapy, 17–27
  basic concepts in, 156
  for cancer, 2
    adjunctive, 6
      aggressiveness of, 15
    adjuvant, timing of, 13
    effectiveness of, 11–12
  for oral neoplasia, 155–163
    interstitial, in oral squamous cell carcinoma treatment, 160
    role in oral neoplasia, 156–157
Radiosensitizers, in oral squamous cell carcinoma treatment, 159
Research abstracts, 30
Reticulosis, radiation for, 19
Retrospective studies, 31–32
Review articles, 31
  descriptive information in, 43–44

Salivary gland tumor, radiation therapy for, 161
  Sarcoma, postvaccinal, in cats, role of inflammation in, 103–109
  Scientific articles, questions regarding, 36
  Sensitivity, of clinical test, 53
  Skin, carcinoma of, radiation for, 23
  Soft tissue sarcomas, radiation for, 25
  Specificity, of clinical test, 53
  Squamous cell carcinoma, of skin, radiation for, 23
  oral, canine, 148
    feline, 150–151
    radiation therapy for, 158–160

Stem cell factor, in mast cell tumors, 89
Surgical oncology, 9–16
  alternatives in, 12–13
  interaction with other therapies, 10–11
  observations about, 11–15
  perspective in, 9–10
Sweat gland, carcinoma of, radiation for, 23
Swelling, local, with mast cell tumor, 100

Textbooks, descriptive information in, 43
  Thyroid, carcinoma of, radiation for, 19
  Tumor(s), development of, promoters of, 105
    excision of, guidelines for surgical margins, 12
    treatment of, patient age and, 14
  Tumor biology, in surgical oncology, 9
    knowledge of, importance of, 13–14

Ulceration, local, with mast cell tumor, 100
Urinary bladder, transitional cell carcinoma of, radiation for, 24
Urogenital carcinoma, radiation for, 24
Usefulness, of clinical test, evaluation of, 52
  of treatment, evaluation of, 56

Vaccine, adjuvants in, as tumor promoters, 106
Validity, of clinical test, evaluation of, 52
  of treatment, evaluation of, 56
Veterinary medical data base, 47
Veterinary oncology, clinical trials in, 29–37
Vincristine, for canine lymphoma, 66

Wound healing, delayed, with mast cell tumor, 99